Catalyst Pharmaceuticals, Inc.
CPRX
Rang în acțiuni
#4167
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables,... Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Preț acțiune
$31.49
Ultima sincronizare: 2026-07-21
Capitalizare de piață
$3.85B
Schimbare (1 zi)
0.00%
Schimbare (1 an)
49.88%
Țară
US
Tranzacționează Catalyst Pharmaceuticals, Inc. (CPRX)
Categorie
Healthcare
Raport P/S pentru Catalyst Pharmaceuticals, Inc. (CPRX)
Raport P/S la data de October 2026 TTM: 6.46
Conform celor mai recente rapoarte financiare și prețului acțiunilor Catalyst Pharmaceuticals, Inc., raportul P/S actual (TTM) este 6.46. La sfârșitul anului 2023, compania avea un P/S de 4.49.
Istoricul raportului P/S pentru Catalyst Pharmaceuticals, Inc. din 2002 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 6.46 | 28.38% |
| 2024 | 5.03 | 12.06% |
| 2023 | 4.49 | -50.02% |
| 2022 | 8.98 | 80.63% |
| 2021 | 4.97 | 71.16% |
| 2020 | 2.90 | -23.05% |
| 2019 | 3.77 | -99.04% |
| 2018 | 394.11 | 0.00% |
| 2017 | 0.00 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2011 | 0.00 | -100.00% |
| 2010 | 37.62 | 0.00% |
| 2009 | 0.00 | 0.00% |
| 2008 | 0.00 | 0.00% |
| 2007 | 0.00 | 0.00% |
| 2006 | 0.00 | 0.00% |
| 2005 | 0.00 | 0.00% |
| 2004 | 0.00 | 0.00% |
| 2003 | 0.00 | 0.00% |
| 2002 | 0.00 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| 10.02 | 55.20% |
US
|
|
| 40.55 | 527.95% |
US
|
|
| 3.96 | -38.66% |
AU
|
|
| - | - |
CH
|
|
| 10.15 | 57.12% |
NL
|
